Table 1.
Baseline | Nitroprusside | |
---|---|---|
Heart rate, beats/min | 61 ± 2 | 80 ± 3* |
Systolic blood pressure, mmHg | 146 ± 3 | 136 ± 4* |
Diastolic blood pressure, mmHg | 77 ± 2 | 73 ± 2* |
Mean blood pressure, mmHg | 99 ± 2 | 91 ± 2* |
Respiratory rate, breaths/min | 11 ± 1 | 11 ± 1 |
Tidal volume, l/breath | 0.70 ± 0.14 | 0.81 ± 0.16 |
Minute ventilation, ml/min | 6.7 ± 0.8 | 7.9 ± 1.0 |
Epinephrine, pg/ml | 67 ± 11 | 82 ± 16 |
Norepinephrine, pg/ml | 174 ± 14 | 215 ± 26 |
Burst frequency, bursts/min | 25 ± 3 | 41 ± 3* |
Burst incidence, bursts/100 heartbeats | 41 ± 5 | 53 ± 4* |
Mean burst area, AU/min | 1.4 ± 0.2 | 2.8 ± 0.4* |
Action potential frequency, APs/min | 191 ± 35 | 439 ± 90* |
Action potential incidence, APs/burst | 8 ± 1 | 11 ± 2* |
Action potential incidence, APs/100 heartbeats | 326 ± 66 | 579 ± 129* |
Mean cluster incidence, clusters/burst | 4.5 ± 0.5 | 5.5 ± 0.7* |
Max cluster incidence, clusters/burst | 9.5 ± 1.0 | 10.9 ± 1.0* |
Max cluster number | 21.6 ± 2.7 | 24.4 ± 3.0* |
Data are means ± SE from n = 13. Average final dose was 0.90 ± 0.05 µg·kg−1·min−1. Data were analyzed with a 1-way repeated-measures ANOVA. Normality was assessed with the Shapiro-Wilk test. If not normally distributed, a Friedman repeated-measures ANOVA on ranks was conducted [respiratory rate, minute ventilation, action potential (AP) incidence (APs/burst), max cluster number]. AU, arbitrary units. Pairwise comparisons were done with the Holm-Sidak method.
P < 0.05 vs. baseline.